secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001493152-24-004783
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic completes $0.5M debt conversion and issues 12 convertible note units
------------------------------------------------------------------------------

- Issued 12 units each with a $25,000 convertible note (convertible at $0.10/share) and warrants to buy 250,000 shares at $0.12/share.
- Converted $500,000 of debt from 4 accredited investors under prior private placement into Subscription Agreements.
- Paid $45,000 placement agent fees to JH Darbie & Co., which also earned 13% of warrants issued.
- This fourth tranche concludes conversion of all notes from prior private placement; company hopes to raise additional funds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315224004783/0001493152-24-004783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315224004783/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer